Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL20239648 | 1.00 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL3216076 | 1.00 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL3225174 | 1.00 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL121072 | 0.96 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL31626793 | 0.96 | CA4 (0.47) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL3205805 | 0.92 | — | — | |
| Glycine SCHEMBL8998221 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL20239641 | 0.92 | — | — | |
| Glycine SCHEMBL15842973 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 | |
| Glycine SCHEMBL9639044 | 0.92 | CA4 (0.44) | CA4GLRA1SLC6A9OR51E2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687486-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | Vivatis Pharma GmbH (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-4687485-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | Vivatis Pharma GmbH (DE) | 2026-02-11 | — | — | EP | claimed |
| WO-2024201327-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | VIVATIS PHARMA GMBH (DE) | 2024-10-03 | — | — | WO | claimed |
| WO-2024201329-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | VIVATIS PHARMA GMBH (DE) | 2024-10-03 | — | — | WO | claimed |
| EP-4687486-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | Vivatis Pharma GmbH (DE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4687485-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | Vivatis Pharma GmbH (DE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201329-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | VIVATIS PHARMA GMBH (DE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024201327-A1 | NOVEL COMBINATIONS COMPRISING KONJAC MANNAN, THEIR COMPOSITIONS AND USES THEREOF | VIVATIS PHARMA GMBH (DE) | 2024-10-03 | — | — | WO | disclosed |
| US-20230086501-A1 | METHOD OF TREATMENT USING SYNERGISTIC DIETARY SUPPLEMENTS TO RELIEVE MOOD FLUCTUATIONS, SKIN BLEMISHES, REDUCED ENERGY LEVELS, AND/OR DIETARY CRAVINGS LINKED TO HORMONAL FLUCTUATIONS OR THE MENSTRUAL CYCLE | Semaine Health (US) | 2023-03-23 | — | — | US | disclosed |
| US-20220105540-A1 | AQUEOUS SLURRIES, COATINGS AND COATED ARTICLES WITH HYDROPHOBIC INORGANIC PARTICLES AND METAL SALTS | THE CHEMOURS COMPANY FC, LLC (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2018111756-A1 | METAL COMPLEXES | NOVUS INTERNATIONAL INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-20180162803-A1 | METAL COMPLEXES | NOVUS INTERNATIONAL, INC. | 2018-06-14 | — | — | US | disclosed |
| US-7294330-B2 | prevent decomposition of steroid ester; inhibit odors | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-11-13 | — | — | US | disclosed |
| EP-1830832-A1 | ZINC-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA | Genzyme Corporation (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099886-A1 | Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration | BIODERM RESEARCH (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070092461-A1 | Novel Hydroxy Acid Complexes for Antiaging and Skin Renovation | BIODERM RESEARCH (US) | 2007-04-26 | — | — | US | disclosed |
| WO-2006072054-A1 | ZINC-CONTAINING TREATMENTS FOR HYPERPHOSPHATEMIA | GENZYME CORPORATION (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20040234466-A1 | Beta-glucuronidase inhibitors for use in deodorants and antiperspirants | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2004-11-25 | — | — | US | disclosed |
| US-4565693-A | Deodorant composition | COLGATE-PALMOLIVE COMPANY (US) | 1986-01-21 | — | — | US | disclosed |
| US-4565693-A | Deodorant composition | COLGATE-PALMOLIVE COMPANY (US) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234466-A1 | Beta-glucuronidase inhibitors for use in deodorants and antiperspirants | GUSB, PON1, IDUA | CA4 437/4885GLRA1 912/4885SLC6A9 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.